Science

AngioChem’s platform technology enables delivery of any drug or drug candidate to the brain.  Our approach creates patentable New Chemical Entities (NCE). We are currently validating our platform technology in humans with ANG1005. In parallel, we are leveraging our technology by creating other NCEs with small molecules, peptides, monoclonal antibodies, siRNA, etc. to treat various brain diseases.